CVS Health (CVS) Stock Could Be A Bargain Despite Its 39% 3 Year Gain

Simply Wall St.10-03

CVS Health has delivered a 3 year gain that contrasts with recent share price weakness, which puts fresh attention on whether today's valuation still lines up with its earnings power. With the stock ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2672446957?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/93625-card/1788942584052","is_english":true,"pubTime":"2026-10-03 06:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2672446957","market":"hk","top_or_hot":-1,"title":"CVS Health (CVS) Stock Could Be A Bargain Despite Its 39% 3 Year Gain","media":"Simply Wall St.","content":"<div>\n<p>CVS Health has delivered a 3 year gain that contrasts with recent share price weakness, which puts fresh attention on whether today's valuation still lines up with its earnings power. With the stock ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-cvs/cvs-health/news/cvs-health-cvs-stock-could-be-a-bargain-despite-its-39-3-yea\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CVS Health (CVS) Stock Could Be A Bargain Despite Its 39% 3 Year Gain</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCVS Health (CVS) Stock Could Be A Bargain Despite Its 39% 3 Year Gain\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-03 06:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-cvs/cvs-health/news/cvs-health-cvs-stock-could-be-a-bargain-despite-its-39-3-yea><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CVS Health has delivered a 3 year gain that contrasts with recent share price weakness, which puts fresh attention on whether today's valuation still lines up with its earnings power. With the stock ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-cvs/cvs-health/news/cvs-health-cvs-stock-could-be-a-bargain-despite-its-39-3-yea\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JOYT","symbol_name":"JPMorgan Equity and Options Total Return ETF","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-cvs/cvs-health/news/cvs-health-cvs-stock-could-be-a-bargain-despite-its-39-3-yea","article_id":"2672446957","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/93625-card/1788942584052"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-cvs/cvs-health/news/cvs-health-cvs-stock-could-be-a-bargain-despite-its-39-3-yea","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2672446957","pubTimestamp":1790979716,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"CVS Health has delivered a 3 year gain that contrasts with recent share price weakness, which puts fresh attention on whether today's valuation still lines up with its earnings power. With the stock last closing at US$86.46 after declines over the past week and month, investors are asking how much of the business story is already reflected in that figure.\n\nOver the past 3 years, CVS Health has returned 38.7%, which puts real weight on the question of whether the current earnings base can...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"JOYT":"JPMorgan Equity and Options Total Return ETF","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","BK4581":"高盛持仓","FEBU":"AllianzIM U.S. Equity Buffer15 Uncapped Feb ETF","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","TACU":"T. Rowe Price Active Core U.S. Equity ETF","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","VGFPF":"Vanguard Funds PLC","BK4585":"ETF&股票定投概念","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU1923622614.USD":"Natixis Thematics Meta R/A USD","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","RGLO":"Global Equity Active ETF","LU0859254822.USD":"T ROWE PRICE GLOBAL VALUE EQUITY \"A\" (USD) ACC","CVS.AU":"Cervantes Corp Ltd","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","IHF":"iShares Dow Jones U.S. Health Ca","LU2357627491.SGD":"TRP GLOBAL VALUE EQUITY \"AH\" (SGDHDG) ACC","CVS":"西维斯健康","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","VOTE":"TCW Transform 500 ETF","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","CDIG":"City Different Investments Global Equity ETF","TSPA":"T. Rowe Price U.S. Equity Research ETF","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4504":"桥水持仓","DECU":"AllianzIM U.S. Equity Buffer15 Uncapped Dec ETF","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","LU1236620750.USD":"HSBC GIF GLOBAL SUSTAINABLE LONG TERM DIVIDEND \"AM2\" (USD) INC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","GXDW":"Global X Dorsey Wright Thematic ETF","BK4550":"红杉资本持仓","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","BK4588":"碎股","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU1236620834.HKD":"HSBC GIF GLOBAL SUSTAINABLE LONG TERM DIVIDEND \"AM2\" (HKD) INC","PMDE":"PGIM S&P 500 Max Buffer ETF - December","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4196":"保健护理服务","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","RTH":"零售指数ETF-HOLDRs"},"translate_title":"CVS Health (CVS) 股票尽管 3 年上涨 39%，但仍可能很便宜","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RTH":0.6,"VOTE":0.9,"IHF":0.6,"JOYT":0.9,"FEBU":0.9,"GXDW":0.9,"CVS":1.5,"TACU":0.61,"CDIG":0.61,"TSPA":0.61,"PMDE":0.9,"RGLO":0.9,"VGFPF":0.9,"CVS.AU":1.5,"DECU":0.9},"content_text":"CVS Health has delivered a 3 year gain that contrasts with recent share price weakness, which puts fresh attention on whether today's valuation still lines up with its earnings power. With the stock last closing at US$86.46 after declines over the past week and month, investors are asking how much of the business story is already reflected in that figure.  Over the past 3 years, CVS Health has returned 38.7%, which puts real weight on the question of whether the current earnings base can carry that performance further. Management's push into an integrated, value based primary care model and ongoing scrutiny of its pharmacy benefit manager role can reshape earnings mix, margin profile, and the timing of cash flows that support the valuation. The analysts covering CVS Health have run their own numbers. See what analysts think CVS Health's shares could be worth.  The issue now is whether CVS Health's current share price is adequately explained by the earnings it is producing today and what those profits may reasonably support over time. To see how CVS Health's recent swing in sentiment compares with other companies where valuation depends on earnings strength, it can help to scan 31 high quality undervalued stocks. AdvertisementIs CVS Health Still Cheap on Earnings? The P/E ratio is a useful lens for CVS Health because earnings still sit at the center of how investors judge its integrated health model. At a current P/E of 22.6x, the stock trades at a premium to its healthcare peer group on 18.6x, yet at a slight discount to the broader healthcare industry average of 24.1x. That split suggests the market is applying some extra weight to CVS Health's profit stream compared with close peers, while still keeping a modest cushion relative to the wider sector. The fair value framework, which looks at factors like margins, risk profile and scale, points to a higher P/E than where CVS Health is priced today, so the current multiple screens as undervalued on that yardstick. Because management is pushing further into value based primary care while facing scrutiny of its pharmacy benefit manager operations, the gap between price and this more tailored benchmark will likely feel comfortable only to investors who are confident the earnings base can absorb those pressures. Explore the numbers behind CVS Health's P/E valuation. NYSE:CVS P/E Ratio as at Oct 2026 The CVS Health Narrative: What Would Justify Today's Price? Narratives pick up where the P/E discussion leaves off for CVS Health by spelling out which mix of future growth, margins and earnings would need to materialise for the stock to be worth meaningfully more or less than it is today on Simply Wall St's Community page. Each scenario ties a fair value estimate to a particular view of CVS Health's potential catalysts and pressure points, so you can track over time which version of events appears to be taking shape. One of the top community narratives on CVS Health: 17% undervalued \"CVS is no longer trying to be a faster pharmacy. It’s trying to be a more complete healthcare system, and that distinction matters…\" Discover why this Narrative puts CVS Health at 17% undervalued. For CVS Health, the valuation story still leaves one crucial issue hanging Price and earnings only tell part of CVS Health's picture, because the research also flags specific risk checks that could change how you weigh everything you have just seen. Take a closer look at 2 warning signs before settling on a valuation.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2672446957","isCrawlerRequest":true}